Liver Diseases Therapeutics Market Research Report by Treatment (Anti Viral Drugs, Chemotherapy Drugs, and Corticosteroids), End User, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030- Product Image

Sale

Liver Diseases Therapeutics Market Research Report by Treatment (Anti Viral Drugs, Chemotherapy Drugs, and Corticosteroids), End User, Region - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

Report
222 Pages
January 2023
Region: Global
360iResearch™
ID: 4904957

UP TO €865EUR$895USD£756GBP OFF until Mar 31^st 2023

The Global Liver Diseases Therapeutics Market size was estimated at USD 15.52 billion in 2022, USD 16.77 billion in 2023, and is projected to grow at a CAGR of 8.14% to reach USD 29.04 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the Global Liver Diseases Therapeutics Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the Global Liver Diseases Therapeutics Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The Global Liver Diseases Therapeutics Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the Global Liver Diseases Therapeutics Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for the market plan. This research report categorizes the Global Liver Diseases Therapeutics Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Treatment, the market is studied across Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids, Immunoglobulin, Immunosuppressant Drugs, and Targeted Therapy.
Based on End User, the market is studied across Ambulatory Surgery Centers and Hospitals.
Based on Region, the market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the Global Liver Diseases Therapeutics Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The Global Liver Diseases Therapeutics Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The Global Liver Diseases Therapeutics Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The Global Liver Diseases Therapeutics Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Liver Diseases Therapeutics Market, including Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Endo International PLC, F. Hoffmann-La Roche AG, Gilead Science Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Protagonist Therapeutics, Inc., and Sanofi S.A..

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Liver Diseases Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Liver Diseases Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liver Diseases Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Liver Diseases Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Liver Diseases Therapeutics Market?
6. What is the market share of the leading vendors in the Global Liver Diseases Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Liver Diseases Therapeutics Market?

Frequently Asked Questions about the Global Liver Diseases Therapeutics Market

What is the estimated value of the Global Liver Diseases Therapeutics Market?

The Global Liver Diseases Therapeutics Market was estimated to be valued at $15.52 Billion in 2022.

What is the growth rate of the Global Liver Diseases Therapeutics Market?

The growth rate of the Global Liver Diseases Therapeutics Market is 8.1%, with an estimated value of $29.04 Billion by 2030.

What is the forecasted size of the Global Liver Diseases Therapeutics Market?

The Global Liver Diseases Therapeutics Market is estimated to be worth $29.04 Billion by 2030.

Who are the key companies in the Global Liver Diseases Therapeutics Market?

Key companies in the Global Liver Diseases Therapeutics Market include Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Bristol, Myers Squibb Company, Dicerna Pharmaceuticals, Inc., Endo International PLC, F. Hoffmann and Gilead Science Inc..

Report Attribute	Details
No. of Pages	222
Published	January 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 15.52 Billion
Forecasted Market Value ( USD ) by 2030	$ 29.04 Billion
Compound Annual Growth Rate	8.1%
Regions Covered	Global
No. of Companies Mentioned	15

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Surge in the incidences of liver diseases worldwide
5.1.1.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
5.1.1.3. Changing lifestyles such as consumption of alcohol and smoking
5.1.2. Restraints
5.1.2.1. Concerns over probable side effects of the medication
5.1.3. Opportunities
5.1.3.1. Ongoing research and development activities for prevention and cure of liver diseases
5.1.3.2. Increasing patent expiration of therapeutics
5.1.4. Challenges
5.1.4.1. Strict government regulations and high cost involved in R&D
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Liver Diseases Therapeutics Market, by Treatment
6.1. Introduction
6.2. Anti Viral Drugs
6.3. Chemotherapy Drugs
6.4. Corticosteroids
6.5. Immunoglobulin
6.6. Immunosuppressant Drugs
6.7. Targeted Therapy

7. Liver Diseases Therapeutics Market, by End User
7.1. Introduction
7.2. Ambulatory Surgery Centers
7.3. Hospitals

8. Americas Liver Diseases Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Liver Diseases Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Liver Diseases Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Product Portfolio Analysis, By Key Player
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. Astellas Pharma Inc.
12.2. AstraZeneca PLC
12.3. Bayer AG
12.4. Bristol-Myers Squibb Company
12.5. Dicerna Pharmaceuticals, Inc.
12.6. Endo International PLC
12.7. F. Hoffmann-La Roche AG
12.8. Gilead Science Inc.
12.9. GlaxoSmithKline PLC
12.10. Johnson & Johnson Services, Inc.
12.11. Merck & Co. Inc.
12.12. Novartis AG
12.13. Pfizer Inc.
12.14. Protagonist Therapeutics, Inc.
12.15. Sanofi S.A.

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2022 VS 2030
FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY REGION, 2030
FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET DYNAMICS
FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2022 VS 2030 (%)
FIGURE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY TREATMENT, 2030
FIGURE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, 2018-2030 (USD BILLION)
FIGURE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD BILLION)
FIGURE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD BILLION)
FIGURE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD BILLION)
FIGURE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, 2018-2030 (USD BILLION)
FIGURE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD BILLION)
FIGURE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY END USER, 2030
FIGURE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD BILLION)
FIGURE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD BILLION)
FIGURE 26. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 27. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 28. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 29. AMERICAS LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 30. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 31. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 32. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 33. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 34. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 35. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 36. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 37. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 38. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 39. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 40. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 41. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 42. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 43. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 44. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 45. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 46. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 47. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 48. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 49. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 50. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 51. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 52. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 53. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 55. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 56. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 57. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE STRATEGIC WINDOW, BY COUNTRY, 2030
FIGURE 58. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 59. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 60. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 61. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 62. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 63. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 64. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 65. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 66. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 67. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 68. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 69. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 70. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 71. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 72. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 73. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 74. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 75. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 76. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 77. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 78. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022List of Tables
TABLE 1. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD BILLION)
TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, 2018-2030 (USD BILLION)
TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTI VIRAL DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2030 (USD BILLION)
TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, 2018-2030 (USD BILLION)
TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD BILLION)
TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD BILLION)
TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2030 (USD BILLION)
TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD BILLION)
TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD BILLION)
TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, 2018-2030 (USD BILLION)
TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD BILLION)
TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD BILLION)
TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD BILLION)
TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD BILLION)
TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, 2018-2030 (USD BILLION)
TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD BILLION)
TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD BILLION)
TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD BILLION)
TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD BILLION)
TABLE 32. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 33. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 34. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 35. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 36. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 37. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 38. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 39. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 40. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 41. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 42. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 43. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 44. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 45. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 46. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 47. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 48. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 49. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 50. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 51. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 52. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 53. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 54. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 55. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 56. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 57. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 58. AUSTRALIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 59. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 60. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 61. CHINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 62. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 63. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 64. INDIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 65. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 66. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 67. INDONESIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 68. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 69. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 70. JAPAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 71. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 72. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 73. MALAYSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 74. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 75. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 76. PHILIPPINES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 77. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 78. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 79. SINGAPORE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 80. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 81. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 82. SOUTH KOREA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 83. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 84. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 85. TAIWAN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 86. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 87. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 88. THAILAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 89. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 90. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 91. VIETNAM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD BILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 96. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 97. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 98. DENMARK LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 99. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 100. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 101. EGYPT LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 102. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 103. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 104. FINLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 105. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 106. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 107. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 108. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 109. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 110. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 111. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 112. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 113. ISRAEL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 114. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 115. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 116. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 117. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 118. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 119. NETHERLANDS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 120. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 121. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 122. NIGERIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 123. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 124. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 125. NORWAY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 126. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 127. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 128. POLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 129. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 130. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 131. QATAR LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 132. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 133. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 134. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 135. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 136. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 137. SAUDI ARABIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 138. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 139. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 140. SOUTH AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 141. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 142. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 143. SPAIN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 144. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 145. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 146. SWEDEN LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 147. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 148. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 149. SWITZERLAND LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 150. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 151. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 152. TURKEY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 153. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 154. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 155. UNITED ARAB EMIRATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 156. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 157. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD BILLION)
TABLE 158. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD BILLION)
TABLE 159. GLOBAL LIVER DISEASES THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 160. GLOBAL LIVER DISEASES THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 161. GLOBAL LIVER DISEASES THERAPEUTICS MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 162. GLOBAL LIVER DISEASES THERAPEUTICS MARKET RANKING, BY KEY PLAYER, 2022
TABLE 163. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 164. GLOBAL LIVER DISEASES THERAPEUTICS MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 165. GLOBAL LIVER DISEASES THERAPEUTICS MARKET MERGER & ACQUISITION
TABLE 166. GLOBAL LIVER DISEASES THERAPEUTICS MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 167. GLOBAL LIVER DISEASES THERAPEUTICS MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 168. GLOBAL LIVER DISEASES THERAPEUTICS MARKET INVESTMENT & FUNDING
TABLE 169. GLOBAL LIVER DISEASES THERAPEUTICS MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 170. GLOBAL LIVER DISEASES THERAPEUTICS MARKET: LICENSE & PRICING